Trial Profile
Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedema.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2011
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 06 Aug 2011 New trial record